Aptose Biosciences — Investor Presentation (January 2025)
20 slides from Aptose Biosciences's investor presentation, Jan 13, 2025
Slide 1: Corporate Presentation January 2025: Tuspetinib in Frontline Triple Drug Therapy for AML
Aptose Precision oncology company developing oral targeted agents to treat hematologic malignancies Corporate Presentation January 2025 Tuspetinib in Frontline Triple Drug Therapy to Treat Newly Diagnosed AML 1 NASDAQ: APTO TSX: APS
Slide 2: AML and Tuspetinib as Third Agent to VEN+AZA
AML (Acute Myeloid Leukemia) • Highly aggressive and deadly cancer of the bone marrow and blood Current Standard of Care Therapy • VEN+AZA (Venetoclax + Azacitidine) two drug therapy • Too few patients achieve responses • Survival too short | median Overall Survival <15mos • VEN drug resistance emer
Slide 3: Key Milestones Achieved and Planned
3 Q4 2024 ASH Key Milestones Achieved and Planned Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 First Report of Response & Safety Data in 1L AML from Ph 1 Triplet Second Report of Response & Safety Data in 1L AML from Ph 1 Triplet Third Report of Response , Safety & Early Durability Data in 1L AML from Ph 1 Tri
Slide 4: Recent Milestones and Press Releases
4 Recent Milestones and Press Releases 4 Aug 30, 2024: Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Aptose - Hanmi TUS Collaboration Agreement to Jointly Develop Tuspetinib Nov 20, 2024: Initiation of TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients
Slide 5: Press Releases: Hanmi Facility, TUSCANY Initiation, $8M Offering
APTOSE Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib ADIGEE Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy US tes ‘oso +=
Slide 6: Press Releases: NCI CRADA, ASH Poster, AACR Publication
APTOSE Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials APTOSE Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML Ce APTOSE Aptose A
Slide 7: Press Releases: Nasdaq Panel Decision, First Patients Dosed
Aptose Announces Positive De: Nasdaq Hearings Panel APTOSE January 9, 2025 APTOSE Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial {2% 9660 on TORONTO, Dc 1, 2104 (GLOBE NEWS ic (Apis othe “Compan rression coy corey dong ay Seated ried eps to Fest
Slide 8: Tuspetinib Kinase Inhibition Profile
8 Tuspetinib Kinase Inhibition Profile – Unique Target Profile Suppresses key oncogenic signaling pathways Avoids targets that compromise safety 8 10nM Test Concentration >90% >75 - 89% >50 - 74% >25 - 49% PDGFR β HPK1 TRKC TRKB JAK2 JAK1 FLT1 MLK2 FGFR 3/4 FLT4 MLK3 MLK1 LOK PKCg LRRK2 ABL RET PDGF
Slide 9: TUS Targets Known VEN-Resistance Mechanisms
9 9 TUS Targets Known VEN - Resistance Mechanisms and May Minimize Drug Resistance FLT3 KIT MCL - 1 PI3K/AKT RAS/ MAPK SYK JAK/STAT TUS Tuspetinib: • Suppresses oncogenic signaling directly • Promotes cancer cell death signaling indirectly
Slide 10: AML Patient Journey: Frontline Therapy Standard of Care
10 10 Newly Diagnosed AML Intensive Chemotherapy (7+3) Low Intensity Therapy (VEN + AZA) AML Patient Journey | Frontline (1L) Therapy | Standard - of - Care (SOC) Palliative Care Hospice 5 - year survival <10% for age >70 1 ; Most survive <1 year Patients “Unfit” for High Dose Chemotherapy Patients
Slide 11: TUS as Superior Third Agent
11 Solution: TUS as Superior 3 rd Agent Proof that Triplet Therapy Works ‒ Gilteritinib (Gilt) added to VEN+AZA boosts CR rate to 90% So, What’s the Problem: Gilt proves “Triplet Therapy” works, but has Limitations ‒ Gilt active in 30% of patients (harbor FLT3 mutation) ‒ Gilt not active in 70% of p
Slide 12: Completed TUS Single Agent and TUS+VEN Doublet Studies
12 Completed TUS Single Agent and TUS+VEN Doublet to Prepare for Triplet in 1L Therapy Treated AML Patients Who Failed Prior Therapies (R/R) with TUS and TUS+VEN 12 Cohort 1: 20 mg QD 2 Cohort 2: 40 mg QD 17 Cohort 3: 80 mg QD 20 Cohort 4: 120 mg QD 32 Cohort 5: 160 mg QD 16 Cohort 6: 200 mg QD 4 TU
Slide 13: TUS and TUS+VEN Safe and Well Tolerated in R/R AML
13 13 TUS and TUS+VEN Safe and Well Tolerated in Highly Treatment Experienced R/R AML TUS+VEN Doublet TUS Single Agent Related to TUS/VEN, n(%) (n=79) Adverse Events Treatment Emergent AEs Related to VEN Treatment Emergent AEs Related to TUS Treatment Emergent AEs Treatment Related AEs Treatment Eme
Slide 14: TUS Single Agent Bone Marrow Blast Reductions
14 14 TUS Single Agent Treatment Bone Marrow Leukemic Blasts │Percent Change from Baseline Blast Reductions Demonstrate Activity Across 4 Dose Levels Activity in Patients Who Failed Prior - VEN and Prior - FLT3i Note: Blast percent change was calculated as 100 X (the lowest post - baseline bone marr
Slide 15: TUS+VEN+AZA Triplet: TUSCANY Trial Ongoing
15 TUS+VEN+AZA Triplet in Newly Diagnosed AML Patients : TUSCANY Trial Ongoing 15 • FLT3 WT (70% of cases) Most Common AML ‒ Only combination being developed for the FLT3 WT population • FLT3 MUT (30% of cases) Intermediate - Risk AML ‒ Potential to increase CR rates and survival of the FLT3 MUT pop
Slide 16: Timeline: Financings, Clinical Trials, and Milestones
16 Q4 2024 ASH ASH EHA Triplet Frontline Therapy In Newly Diagnosed AML Timeline : Financings , Clinical Trials, and Milestones ASH EHA Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 TUS+VEN+AZA Ph 1 Triplet Study Initiated 1L Triplet Dosing in Newly Diagnosed AML First Report of Response and Safety Data in 1L A
Slide 17: Nasdaq Market Summary and Capital Structure
17 APTO Nasdaq Market Summary • Market Cap $14M • 52 - Week range $0.13 to $2.60 • Avg Volume 6.6 million shares Investment Thesis: Multiple Clinical Data Forthcoming and Hanmi Collaboration Derisks Investment 17 2024 Financing Activity • $10M Hanmi Advance (Debt) Aug. 2024 • $8M Financing Nov. 2024
Slide 18: Investment Thesis
Investment Thesis Hanmi Collaboration Reduces Investment Risk • The Hanmi TUS collaboration (expected Q1/2025) will provide significant capital to fund the TUS Triplet Study • Hanmi's advance of $10M will be offset against the collaboration's upfront payment Proven Effectiveness of Frontline Triplet
Slide 19: Aptose Disclosure
19 19 Aptose Disclosure This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or i nvi tation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/
Slide 20: Thank you
Thank you APTOSE BIOSCIENCES
Aptose Biosciences — Investor Presentation (January 2025) on 6ix